|
EP3714902A1
|
|
Stabilization of pharmaceutical compositions comprising polysorbate
|
|
WO2020115213A1
|
|
Solvate of a selective jak1 inhibitor
|
|
WO2020115212A1
|
|
Crystalline phosphate salt of selective jak1 inhibitor upadacitinib
|
|
EP3339329A1
|
|
Selective oxidation of maltodextrin and its use in the preparation of water-soluble iron (iii) carboxymaltose complexes
|
|
EP3333167A1
|
|
Solid forms of venetoclax
|
|
WO2017068051A1
|
|
Peg-based dendron and process for producing the same
|
|
EP3272348A1
|
|
Pharmaceutical composition comprising idelalisib
|
|
EP3190122A1
|
|
A novel synthetic pathway towards solithromycin and purification thereof
|
|
EP3218478A1
|
|
Predicting productivity in early cell line development
|
|
EP3218514A1
|
|
Predicting genetically stable recombinant protein production in early cell line development
|
|
EP3144393A1
|
|
A synthetic pathway towards apremilast
|
|
WO2016042121A1
|
|
Spray-freeze drying of polyelectrolyte nanoparticles containing the protein drug
|
|
WO2016016279A1
|
|
Novel hydrates of dolutegravir sodium
|
|
EP3106457A1
|
|
A novel synthetic pathway towards apremilast
|
|
US2016346207A1
|
|
Solid Pharmaceutical Compositions Of Androgen Receptor Antagonists
|
|
EP3045461A1
|
|
Processes for preparing dolutegravir and analogues thereof
|
|
EP3034496A1
|
|
Novel solvates of n-[2-[(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1h-isoindol-4-yl]acetamide
|
|
WO2015032972A1
|
|
Nanoformulation of g-csf for non-parenteral delivery
|
|
WO2015032981A1
|
|
Erythropoietin conjugates having oral bioavailability
|
|
WO2015032971A1
|
|
Polymer selection for preparation of nps with high protein loading
|
